KDR and anemia: For cabozantinib-treated patients, some events, such as diarrhoea, nausea, and anaemia, were reported at a higher rate (≥5% difference) for patients previously treated with sunitinib compared with pazopanib, suggesting that first-line VEGFR TKI therapy may influence the tolerability of subsequent treatment with cabozantinib.